论文部分内容阅读
为探讨胚胎胸腺细胞（ＦＴＣ）移植的作用机理，采用单克隆抗体免疫荧光法检测了１９例淋巴细胞癌变患者ＦＴＣ移植前后Ｔ淋巴细胞亚群分布。结果表明：ＦＴＣ移植前患者ＣＤ＋３，ＣＤ＋４，ＣＤ＋４／ＣＤ＋８低于正常对照组（Ｐ＜００１），ＣＤ＋８高于对照组（Ｐ＜００１）；ＦＴＣ移植后ＣＤ＋３，ＣＤ＋４较移植前明显增高（Ｐ＜００１）；ＣＤ＋８显著降低（Ｐ＜００１），ＣＤ＋４／ＣＤ＋８比值亦有显著提高（Ｐ＜００１）；小淋巴细胞总数增加与ＣＤ＋３的变化一致。这些变化在ＦＴＣ移植后２个月更为显著。同时，临床疗效表明：患者症状明显改善，生活质量明显提高，随访一年，无复发现象。作为认为ＦＴＣ移植后，Ｔ前体细胞在胸腺组织内实现免疫重建，有效地升高ＣＤ＋４降低ＣＤ＋８，恢复ＣＤ＋４／ＣＤ＋８比值。
In order to investigate the mechanism of embryonic thymocyte (FTC) transplantation, the distribution of T lymphocyte subsets before and after FTC transplantation in 19 lymphocyte cancerous patients was detected by monoclonal antibody immunofluorescence assay. The results showed that CD+3,CD+4,CD+4/CD+8 in patients before FTC transplantation were lower than those in normal control group (P<001), and CD+8 was higher than in control group (P<001). CD+3 and CD+4 after FTC transplantation were more obvious than before transplantation. Increased (P<001); CD+8 decreased significantly (P<001), CD+4/CD+8 ratio also increased significantly (P<001); the increase in total number of small lymphocytes was consistent with that of CD+3. These changes were more pronounced 2 months after FTC transplantation. At the same time, the clinical efficacy showed that the symptoms of the patients were significantly improved and their quality of life was significantly improved. There was no recurrence after one year of follow-up. It is believed that after FTC transplantation, T precursor cells achieve immune reconstitution in the thymus tissue, effectively increasing CD+4 and decreasing CD+8, restoring the CD+4/CD+8 ratio.